Back

Frailty and associated outcomes in patients with transthyretin cardiac amyloidosis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: The different faces of cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Carlo Fumagalli

University of Campania Luigi Vanvitell, Naples (Italy)

9 More presentations in this session

Presentation thumbnail
Sustained paradoxical vasodilation and blood pressure lowering in response to sympathetic stimulation as markers of disease severity and poor survival in primary AL amyloidosis.
Doctor K. Stamatelopoulos (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Changes in the diagnostic landscape of transthyretin amyloid cardiomyopathy (ATTR-CM): a comparison of tests ordered and test Intervals in 2020 Q4 and 2023 Q4
Mr P. Collins (London, GB)
Abstract Slides Video
Presentation thumbnail
Cardiac transthyretin amyloidosis in patients with conduction system disease
Doctor J. Pudich (Ostrava, CZ)
Abstract Slides Video
Presentation thumbnail
ATTR cardiac amyloidosis after lumbar spinal stenosis- a prospective cohort study
Doctor P. Eldhagen (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Clinical and laboratorial profile of patients with ATTR cardiomyopathy: comparison between wild type and p.Val142Ile forms in the Brazilian population
Associate Professor M. Simoes (Ribeirao Preto, BR)
Abstract Slides Video

Access the full session

Session thumbnail
The different faces of cardiac amyloidosis

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
The relevant role of frailty in patients with transthyretin amyloidosis cardiomyopathy
thumbnail
Congress Presentation
Multiparametric assessment of frailty in transthyretin amyloidosis cardiomyopathy and its correlation with prognostic staying scores.
thumbnail
Congress Presentation
Malnutrition, frailty, and physical performance in transthyretin cardiac amyloidosis: insights from a prospective multicenter cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources